The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events
Open accessAbstract
Background and Purpose— The goal of this study was to examine the influence of preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and compare the efficacy of clopidogrel versus aspirin (acetylsalicylic acid, ASA) in patients with such disease. Methods— Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. Two composite end points were used: (1) IS, MI, or vascular death and (2) IS, MI, or rehospitalization for ischemia. Results— In the CAPRIE population, prior IS and MI each were statistically significant predictors of subsequent ischemic events. Compared with the overall population, patients with preexisting symptomatic atherosclerotic disease had elevated event rates for the end point of IS, MI, or vascular death; 3-year rates were 20.4% with clopidogrel and 23.8% with ASA (absolute risk reduction, 3.4%; 95% CI, −0.2 to 7.0; number needed to treat, 29; relative risk reduction, 14.9%; P =0.045). Similar results were obtained for the end point of IS, MI, or rehospitalization for ischemia; 3-year event rates were 32.7% with clopidogrel and 36.6% with ASA (absolute risk reduction, 3.9%; 95% CI, −0.4 to 8.1; number needed to treat, 26; relative risk reduction, 12.0%; P =0.039). Conclusions— CAPRIE patients with a history of prior symptomatic atherosclerotic disease had a high rate of subsequent ischemic events. The absolute benefit of clopidogrel over ASA seemed to be amplified in such high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02567-5 · Cited by 409
Self-citation
Cited by
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Scientific and therapeutic advances in antiplatelet therapy
Bhatt, D. L., & Topol, E. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd985 · Cited by 407
Self-citationPatients with peripheral arterial disease in the CHARISMA trial
Cacoub, P. P., Bhatt, D. L., Steg, P. G., Topol, E. J., Creager, M. A., & for the CHARISMA Investigators (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn534 · Cited by 360
Self-citationClinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Self-citation
Metadata
- Authors
- Ringleb, P. A., Bhatt, D. L., Hirsch, A. T., Topol, E. J., & Hacke, W.
- Venue
- Stroke
- Published
- 2004-02
- Volume
- 35
- Issue
- 2
- Pages
- 528-532
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W1996134888
- Cited by
- 183
- References
- 4
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. https://app.cochat.ai/papers/10.1161/01.str.0000110221.54366.49
- The paper
- Ringleb, P. A., Bhatt, D. L., Hirsch, A. T., Topol, E. J., & Hacke, W. (2004). Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. Stroke. https://doi.org/10.1161/01.str.0000110221.54366.49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.